




J. Afr. Ass. Physiol. Sci. 8 (1): 62-70, July 2020 
 
Journal of African Association of Physiological Sciences 







Adverse effect of graded Ciprofloxacin oral intake in male 
Sprague-Dawley rats 
 
Y.D. Igbayilola1, W.A. Saka1, O.S. Aina2*, A.M. Mofolorunso2, A.O. Oyabambi3, A.O. 
Morakinyo2*  
Departments of Physiology, 1*,2College of Medicine of the University of Lagos, Lagos, Nigeria, 3College of Health 
Sciences, Ladoke Akintola University of Technology, Ogbomoso, Nigeria, 2*Lagos State University College of 




profile, oxidative stress, 























Background: Ciprofloxacin (CF) is a very popular antibiotics used for therapeutic prospects. 
This study was investigated to determine the effect of graded CF oral intake on lipid profile, 
hepato-reno, antioxidant and cardiovascular functions in Sprague-Dawley rats. Methods: Male 
Sprague-Dawley rats (120-150g) were grouped into 4 equal groups. Group A; control, received 
1 ml of normal saline/100g bw, group B, C and D received CF orally at 5, 10 and 20mg/kg 
respectively. After 7days daily treatments, blood sample was collected via retro-orbital puncture 
to obtain serum sample for the determination of cholesterol (CHOL), triglyceride (TG), high 
density lipoprotein (HDL) and low density lipoprotein (LDL). Urea, creatinine, aspartate amino 
transferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) were 
investigated. Superoxide dismutase (SOD), reduced glutathione (GSH), catalase (CAT), 
malonaldehyde (MDA), blood pressure (BP) and heart rate (HR) were measured via femoral 
cannulation under anesthesia using urethane and 1% α-chloralose. Results: There was a 
significant decrease (p<0.05) in CHOL in group C while TG, LDL, urea significantly reduced 
in groups B and C and significantly increased in group D (p<0.05). Creatinine, ALT and ALP 
upregulated in group D (p<0.05) while AST downregulated in groups C and D. GSH and CAT 
downregulated in groups B, C and D while SOD reduced significantly (p<0.05) in groups B and 
D. MDA downregulated in groups B and C and upregulated (p<0.05) in group D (p<0.05). BP 
and HR significantly increased in groups B, C and D compared with control (P<0.05). 
Conclusion:  This study showed that oral CF intake at 5mg/kg and 10mg/kg had no adverse 
effect on lipid profile, hepato-reno and antioxidant functions. However, CF at 20mg/kg may 
predispose to dyslipidaemia, hepato-reno dysfunction and increased oxidative stress. CF at 
20mg/kg may exert a deleterious effect cardiovascular function. 
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INTRODUCTION   
Antibiotics are substances derived from microorganisms 
that inhibits or destroy the growth of other micro-
organisms and are used to treat infections caused by 
organisms that are sensitive to them, usually bacterial or 
fungi (Douglas et al., 2016). They alter the normal 
microbial content in specific region of the body such as 
lungs, bladder and intestine by destroying one or more 
groups of harmless or beneficial organisms, which may 
result in infection due to over growth of resistance 








likely to occur with broad-spectrum antibiotics that exert 
their effect against a wide variety of organisms (Douglas 
et al., 2016).  
Fluoroquinolones are anti-microbial agents, with broad 
spectrum of bacterial activity against both Gram-
positive and Gram-negative bacterial (Oliphant and 
Green, 2002; Shenoy et al., 2011). They are bacterial 
agents that exert their bactericidal action by inhibiting 
the action of bacterial enzymes DNA gyrase, a type II 
topoisomerase and topoisomerase IV, thereby, 
preventing cell division (Laurence and Parker, 2008). 
They are effective against urinary, gastrointestinal, skin, 
respiratory, bone and joint infections (Blondeau, 1999) 
and are the most commonly prescribed class of 
antibiotics, being utilized widely in the treatment of 
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respiratory, urinary tract, gastrointestinal and abdominal 
infections (Gootz et al., 1990; Kumar et al., 2011). 
Fluoroquinolones are well tolerated in patients but their 
uses have been associated with some adverse effects, 
including gastrointestinal discomfort, cutaneous 
reactions e.g. phototoxicity, juvenile joint toxicity and 
adverse central nervous system (CNS) effects (Nau et 
al., 2010; Ftai et al., 2013).  
 
Ciprofloxacin is a bactericidal agent that has good 
activity against many gram-negative bacilli and cocci, 
including most species and strains of Pseudomonas 
aeruginosa, Klebesiella spp., E. coli, Enterobacter, 
Campylobacter, Shigella, Salmonella, Aeromonas, 
Haemophilis, Proteus, Yersinia, Serratia and Vibrio spp 
(Plumb, 2005) and also active against Bordetella 
bronchisepta, Brucella spp., Chlamydia spp. and 
Mycoplasma spp (Plumb, 2005). It has been shown to 
have good bioavailability after oral administration, 
excellent tissue penetration and it is considered 
relatively safety (Ball and Tillotson, 1995; Papich, 
1998). For these reasons, it is used in a variety of human 
clinical infections (Such and Lorber,1995), particularly 
urinary tract infections where it is used at a dose of 10 
mg/ kg/ day for about 1 to 12 weeks.  
 
In the current practices of anti-infective therapy, it has 
been shown to be very popular fluoroquinolone used for 
therapeutic prospects. In recent years, over 20 million 
outpatient prescriptions were written for ci profloxacin. 
In USA, ciprofloxacin is the 35th most commonly used 
drug, and the 5th most commonly prescribed antibiotics 
(Gyawale et al., 2009). The available clinical evidence 
suggests the potential enhanced efficacy of this drug for 
the treatment of various communities acquired and 
nosocomial infections, e.g. urinary, biliary, respiratory, 
skin and neuronal pathogens (John and Weigelt, 2007) 
and onsequent to the broad-spectrum, flouroquinolones 
were associated with a variety of adverse effects 
(Dollery, 1999).  
 
Studies on the safety of fluoroquinolones are relatively 
scarce though there are few reports on toxicity of 
Ciprofloxacin (Abd-Allaah et al., 2000; Baykal et al., 
2005; Demir et al., 2007; Pfister et al., 2007; Khaki et 
al., 2008). These studies needed to be investigated 
further. Hence, the study was designed to investigate the 
effect of graded dose of oral Ciprofloxacin intake on 
lipid profile, hepato-reno function, oxidative balance 
and cardiovascular responses in Sprague-Dawley rats. 
 
MATERIALS AND METHODS  
Drugs  
Drug (Ciprofloxacin 500mg/Tablet) was obtained from 
a Pharmacy store in Idi-Araba, Lagos Nigeria. 
Animals  
Healthy male Sprague-Dawley rats weighing between 
120-150 grams were obtained from the animal house of 
Physiology department, College of Medicine, University 
of Lagos. They were acclimatized for two weeks before 
the experiment. They were each fed with standard rodent 
chow and water ad libitum. The experimental procedures 
adopted were in accordance with the provisions of the 
Experimentation Ethics Committee on Animals Use of 
the College of Medicine of the University of Lagos, 
Lagos State and the United States National Academy of 
Sciences Guide for the Care and Use of Laboratory 
Animals (2011).  
 
Dosage preparation 
Twenty-four healthy Sprague-Dawley rats were grouped 
into four groups of equal rats and treated as follows and 
administered doses were calculated equivalent of human 
therapeutic dose (FDA, 2002). The stock solution was 
25%(w/v) 
Control group received 1ml of normal saline per 
100g/bw 
Group B received 5mg/kg at 1ml/100g resultant solution 
(low dose) 
Group C received 10mg/kg at 1ml/100g resultant 
solution (normal dose); 
Group D received 20mg/kg at 1ml/100g resultant 
solution (high dose). 
 
Collection of blood sample 
Five (5ml) of blood sample was taken by retro-orbital 
puncture using heparinized capillary tube  into the plain 
bottles and allowed to clot for 1 hour at 4◦c. It was then 
centrifuged at 3,000 rpm for 10 minutes. The serum 
samples were obtained and stored at -20◦c until assayed 
(Morakinyo et al., 2018)  
 
Blood lipids 
Serum lipid levels of triglyceride (TG), cholesterol 
(CHOL), low density lipoprotein (LDL) and high 
density lipoprotein (HDL) after treatment were 
determined by automatic biochemistry analyzer 
(Mindray BS-120, Chema Diagnostica, Italy) using 
diagnostic kits for each, purchased from BioSystems® 
(S.A Costa Brava of Barcelona, Spain). 
 
Liver and kidney functions 
Albumin (ALB), alkaline phosphatase (ALP), alkaline 
amino transferase (ALT), aspartate amino transferase 
(AST) and albumin were determined using serum 
samples by an automated analyzer (Mindray BS-120, 
Chema Diagnostica, Italy). The same machine was 
equally used for the determination of urea and creatinine.  
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Determination of superoxide dismutase (SOD) activity 
Briefly; SOD activity was measured by the inhibition 
autoxidative capacity of pyrogallol. The SOD activity 
was evaluated using a spectrophotometer at 420 nm. A 
calibration curve was constructed using SOD as 
standard. A 50% inhibition of autoxidation of pyrogallol 
was defined as one SOD unit (DinizVilela et al., 2016) 
 
Determination of reduced glutathione (GSH) activity 
The protein content of the serum samples was initially 
precipitated by metaphosphoric acid (MPA) at the ratio 
of 1:1. The samples were centrifuged at 3000rpm for 10 
minutes. The supernatant was collected and mixed with 
sodium phosphate buffer (0.1M, pH 7.4), containing 
EDTA (5mM) and ortho-phthaldialdehyde (1 mg/mL in 
methanol). The mixture was incubated in the dark at 
room temperature for 15 min and fluorescence was 
measured at 350 nm (excitation) and 420 nm (emission). 
A standard curve of GSH (0.001–0.1 mM) was used for 
linear regression (DinizVilela et al., 2016) 
 
Determination of catalase (CAT) activity 
Briefly, serum sample (1ml) was mixed with 49 ml of 
distilled water to give a 1 in 50 dilution of the sample. 
The assay mixture contained 4ml of H2O2 solution (800 
μmoles) and 5ml of Phosphate buffer in a 10ml flat 
bottom flask. 1ml of properly diluted enzymes 
preparation was rapidly mixed with the reaction mixture 
by a gentle swirling motion. The reaction was run at 
room temperature. A 1ml portion of the reaction mixture 
was blown into 2ml of dichromate acetic acid reagent at 
60s intervals. Catalase (CAT) activity was determined 
by measuring the exponential disappearance of H2O2 at 
240nm and expressed in units/mg of protein (Aebi, 
1984). 
 
 Determination of malonaldehyde (MDA) activity 
Briefly, the most abundant individual aldehyde resulting 
from lipid peroxidation breakdown in biological systems 
and this is based on its interaction with thiobarbituric 
acid (TBA) to form pink complex with absorption at 
535nm.  Absorbance was read using Microlab 300 
recording spectrophotometer (UV 160) in all 
measurements (Uchiyama and Mihara, 1978). 
  
Cardiovascular analysis  
Anesthesia 
After 7 days of daily treatment, solution of 25%(w/v) 
urethane and 1% alpha chloralose were administered as 
an aesthesia via intraperitoneal route (i.p) to the rats at a 
dose of 5ml/kg body weight (Oloyo et al., 2019 
Blood pressure and Heart Rates Measurement   
Blood Pressure and Heart Rate (HR) were determined 
via cannulation of carotid artery (Oloyo et al., 2011) with 
polyethylene cannula, connected to 1% heparinized 
normal saline with a 3-way channel connector. The 
cannulated artery was secured tightly with thread and 
connected to Power lab pressure transducer (model 
SP844, Physiological Pressure Transducer, AD 
Instrument (Power Lab-4/24T) which was in turn 
attached through MLACH11 Grass adapter cable to a 
computerized data acquisition system with Labscribe 
software.  Heart rates were determined by counting the 
number of arterial pulses at sampling frequency of 
sample of 5/s. The Systolic Blood Pressure (SBP), 
Diastolic Blood Pressure (DBP) were obtained directly 
from the tracing as the peak and the base of the arterial 
pulses respectively. Mean Arterial Pressure (MAP) was 
determined from the following formula:1/3(SBP-DBP) 
+ DBP. (Gobel et al., 1978).    
  
Statistical analysis 
All results are presented as the mean standard error of 
mean±(SEM). Statistical analyses were conducted using 
Graph Pad Prism Software (GraphPad, Inc., La Jolla, 
CA, USA). Data analyses were performed by one-way 
analysis of variance (ANOVA) with post hoc Tukey's 
multiple comparison test. Statistical significance was set 
at p < 0.05. 
 
RESULTS 
Effect of graded dose of Ciprofloxacin on serum levels 
of TG, LDL, HDL and CHOL 
 There was a significant decrease (p<0.05) in TG levels 
in groups B (0.65±0.03), C (0.60±0.03) with a 
significant increase in group D (0.10±0.04) compared 
with control (p<0.05), groups B (0.65±0.03), and C 
(0.60±0.03). LDL showed a significant decrease 
(p<0.05) in groups B (0.83±0.03) and C (0.82±0.04) and 
significant increase in group D (1.11±0.01) compared 
with control (1.00±0.01) groups B (0.83±0.03) and C 
(0.82±0.04). However, there was no significant 
difference in HDL levels in groups B (1.18±0.06), C 
(1.05±0.06), and D (1.26±0.04) compared with control 
(p>0.05). The result also showed a decrease in CHOL 
level in group B (2.53±0.06) and D (2.51±0.07) but not 
significant (p>0.05) compared with control, however, a 
significant decreased was observed in group C 
(2.22±0.08) compared with control (2.76±0.09) and 
group B (2.53±0.06) (Table 1). 
  
Effect of graded dose of Ciprofloxacin on serum levels 
of urea and creatinine 
The urea level was significantly decrease (p<0.05) in 
groups B (6.63±0.12) and C (6.16±0.14) with a 
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significant increase p<0.05) in group D (7.78±0.12) 
compared with control, B (6.63±0.12) and C 
(6.16±0.14) (Figure 1). Figure 2 revealed a 
significant increase (p<0.05) in creatinine level in 
group D (80.33±1.98) compared with control 
(64.50±2.28), B (73.33±3.08) and C (73.40±3.34) 
(p<0.05)  
 
Effect of graded dose of Ciprofloxacin on serum 
levels Albumin, AST, ALT and ALP 
There was no significance difference (p>0.05) in 
albumin (ALB) levels in groups B (33.50±1.20), C 
(32.80±0.96) and D (35.83±0.54) compared with 
control, however, ALB level significantly elevated 
(p<0.05) in group D (35.83±0.54) compared with group 
C (32.80±0.96). The results also showed a significant 
decrease (p<0.05) in AST level in groups B 
(96.83±1.31) and C (96.20±1.88) and significant 
increase in group D (109.67±1.04) compared 
control (105.00±1.33), B (96.83±1.31) and C 
(96.20±1.88). There was a significant increase 
(p<0.05) in ALT level in group D (46.66±1.0) 
compared with control (39.16±1.10), B 
(41.50±0.61) and C (46.66±1.0). A significant 
increase (p<0.05) was observed in ALP level in 
group D (43.00±1.77) compared with control 
(35.33±2.76), B (31.66±2.65) and C (31.40±2.58) 
(Table 2). 
Effect of graded dose of Ciprofloxacin on serum 
activity of GSH, SOD, CAT and MDA level 
Results from antioxidant assay showed a significant 
decrease(p<0.05) in GSH activity in groups B 
(0.77±0.04) and D (0.92±0.03) compared with control 
(1.11±0.03) and a significant increase (p<0.05) in 
group D (0.92±0.03) compared with group B 
(0.77±0.04) with a significant decrease (p<0.05) 
compared with group C (1.08±0.02) (Figure 3a)  
 
A significant decrease (P<0.05) was observed in 
SOD activity groups B (4.80±0.06), C (5.25±0.07) 
and D (5.00±0.05) compared with control (5.80±0.09)   
and significantly increased (P<0.05) in group C 
compared with group B (p<0.05) (Figure 3b).  
Figure 3c showed a significant decrease (P<0.05) in 
CAT activity groups B (23.01±1.04), D   compared 
with control (31.07±1.05) and significantly 
decreased (P<0.05) in group D, compared 
(26.03±1.00) with group C (31.13±1.02).  
Ciprofloxacin produced a significant decrease 
(p<0.05) in MDA level in groups B (1.56±0.02) and 
C (1.35±0.01) with a significant increase (p<0.05) in 
group D compared with control (p<0.05). Also, 
MDA level significantly elevated (p<0.05) in group 
D (2.01±0.02) compared with group B (1.56±0.02) 
and C (1.35±0.01) (Figure 4). 
 
Table 1: Serum levels of TG, CHOL, HDL and LDL in rats treated with graded dose of Ciprofloxacin 
Parameters 
(mmol/l) 
Control Group B Group C Group D 
TG 0.86±0.02 0.65±0.03* 0.60±0.03* 0.10±0.04*a1 
CHOL 2.76±0.09 2.53±0.06 2.22±0.08*a 2.51±0.07 
HDL 1.18±0.06 1.05±0.06 1.20±0.08 1.26±0.04 
LDL 1.00±0.01 0.83±0.03* 0.82±0.04* 1.11±0.01*a1 
Values represent Mean ± SEM. n=6.  Significant (#p<0.05 vs. group A, ap<0.05 vs group B, 1p<0.05 vs. group C) 
 
Effect of graded dose of Ciprofloxacin on 
cardiovascular parameters 
 The cardiovascular analysis shows a significant 
decrease (P<0.05) in SBP in group C (115.41±8.75) 
with a significant increase in group D 
(129.11±9.96) compared with control 
(103.05±4.75) and group B (105.87±5.81)  
The results also showed a significant increase 
(P<0.05) in DBP in groups, B (76.22±3.08)  C 
(84.42±3.49) and D (96.74±3.00) with a significant 
increase (P<0.05) in group D (96.74±3.00) 
compared with control, groups B and C (P<0.05). A 
significant decrease (p<0.05) in PP was observed in 
groups B (,29.64±2.63), C (30.98±2.28) and D 
(32.36±2.86) compared with control. 
 
Effect of graded dose of Ciprofloxacin on 
cardiovascular parameters 
 The cardiovascular analysis shows a significant 
decrease (P<0.05) in SBP in group C (115.41±8.75) 
with a significant increase in group D(129.11±9.96) 
compared with control(103.05±4.75) and group B
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Table2: Serum levels of ALB, AST, ALT and ALP in rats treated with graded dose of Ciprofloxacin 
Parameters Control Group  B Group C Group D 
ALB (g/L) 34.66±0.71 33.50±1.20 32.80±0.96 35.83±0.541 
AST (IU) 105.00±1.33 96.83±1.31 * 96.20±1.88 * 109.67±1.04*a1  
ALT (IU) 39.16±1.10 41.50±0.61 42.40±1.12 46.66±1.0*a1 
ALP (IU) 35.33±2.76 31.66±2.65 31.40±2.58 43.00±1.77*a1 
Values represent Mean ± SEM. n=6Significant (#p<0.05 vs. group A, ap<0.05 vs group B, 1p<0.05 vs. group C) Figure 4: 
Serum MDA level in rats treated with graded Ciprofloxacin. Values represent Mean ± SEM. n=6 Significant (#p<0.05 vs. 
group A, ap<0.05 vs group B, 1p<0.05 vs. group C) 
 
 (105.87±5.81). The results also showed a 
significant increase (P<0.05) in DBP in groups, B 
(76.22±3.08)  C (84.42±3.49) and D (96.74±3.00) 
with a significant increase (P<0.05) in group D 
(96.74±3.00) compared with control, groups B and 
C (P<0.05). A significant decrease (p<0.05) in PP 
was observed in groups B (,29.64±2.63), C 




Fig. 1: Serum level of urea in rats treated with 
graded Ciprofloxacin. Values represent Mean ± SEM. 
n=6; Significant (#p<0.05 vs. control, ap<0.05 vs group 
B, 1p<0.05 vs. group C) 
 
 
Fig. 2: Serum level of creatinine in rats treated with 
graded Ciprofloxacin. Values represent Mean ± SEM. 
n=6.  Significant (#p<0.05 vs. control, ap<0.05 vs group 
B, 1p<0.05 vs. group C)
 
Fig. 3: Serum levels of GSH (a), superoxide dismutase, SOD 
(b) and Catalase, Cat. (c) in rats treated with graded 
ciprofloxacin. Values represent Means ± SEM. n=6.  
Significant (#p<0.05 vs. group A, ap<0.05 vs group 
B, 1p<0.05 vs. group C) 
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Fig. 4: Serum MDA level in rats treated with graded 
Ciprofloxacin. Values represent Mean ± SEM. n=6.  
Significant (#p<0.05 vs. group A, ap<0.05 vs group B, 
1p<0.05 vs. group C).  
DISCUSSION  
Ciprofloxacin inhibits an enzyme called DNA gyrase 
that is an essential component of the mechanism that 
posse’s genetic information onto daughter cell during 
division. The use of ciprofloxacin products for medical 
benefits has played an important role and it is a second-
generation fluoroquinolines. It was primarily eliminated 
by renal exaction; however, the drug was also 
metabolized and partially cleared through the intestine. 
It is an antibiotic that can treat a number of infections 
(Fush et al., 1994).        
 Though, results for the present study show no risk 
of lipid disorders in the groups administered with 10 
and 15mg/kg bw, however, 20mg/kg dose gave rise 
to elevated triglyceride and elevated   low density 
lipoprotein as there was a significant decrease in TG 
and LDL. Elevated triglyceride and elevated low 
density lipoprotein are well known risk factors for 
dyslipidaemia and development of arthrosclerosis. 
Previous study by Fatai et al., (2013) had earlier 
reported heart diseases and blood vessel disorder in 
rats treated with Ciprofloxacin.  
The significant increase in urea and creatinine in the 
group treated with 20mg/kg bw is suggestive of 
kidney disorder or damage. This is an agreement the 
previous study which reported that over dose of 
ciprofloxacin can lead to acute renal toxicity and 
death (Fatai et al., 2013).  The liver is a major 
metabolic organ and plays a key role in lipid 
metabolism. Depending on species it is, more or less, the 
hub of fatty acid synthesis and lipid circulation through 
lipoprotein synthesis (Mguyen et al., 2008). Eventually, 
the accumulation of lipid droplets results in hepatic 
steaosis, which may develop as a consequence of 
multiple dysfunctions such as alterations in β-oxidation, 
very low density lipoprotein secretion, and pathways 
involved in the synthesis of fatty acids (Mguyen et al., 
2008).  
The present study demonstrated a significant 
elevation of AST, ALT and ALP at 20mg/kg bw 
suggestive of liver damage. This agrees with 
previous study by (Orman et al., 2001; Fatai et al., 
2013). It was observed that ciprofloxacin induced liver 
injury marked with elevated liver enzymes (AST, ALT 
and ALP). Elevated ALP is associated with cholestatic 
disorder, intrahepatic and extrahepatic obstruction to 
bile flow (Freidman et al., 1997) while elevated ALT is 
associated with toxic hepatitis, chronic hepatitis and 
Cholestatic hepatitis (1999) and Hirsch, (2009) 
Bhagirat et al., (2008) and Hirsch, (2009) demonstrated 
that ciprofloxacin induced hepatotoxicity in most patient 
treated with over doses is characterized by elevated 
levels of AST, ALT and ALP.  Halliwell and Gutteridge, 
(1999) and Hirsch, (2009) also reported that 
ciprofloxacin induced hepatic failure, hepatitis, 
cholestatic jaundice and acute liver injury marked by 
elevated level of liver enzymes due to the fact that 
Ciprofloxacin has a potential hepatotoxic agent. This sis 
in agreement with the present study as 
Ciprofloxacin at 20mg/kg bw produced marked 
elevation of AST, ALT and ALP. 
Oxidative stress results when the antioxidant system is 
overwhelmed by the generation of excess reactive 
oxygen species (ROS) (Halliwell and Gutteridge, 1999). 
These reactive species like superoxide radical anion (O-
2), hydrogen peroxide (H2O2) and hydroxyl radicals (HO-
) cause severe damage to macromolecules, tissues and 
organs through the process of lipid peroxidation (LPO), 
protein modification and DNA strand breaks (Sun and 
Chen, 1998; Zaidi and Banu, 2004). Oxidative stress 
resulting from the generation of these free radicals is 
known to contribute immensely to several pathological 
conditions like aging, cancer, cardiovascular disorder, 
neurodegenerative diseases among others (Halliwell and 
Gutteridge, 1999; Abuja and Albertini, 2001). 
 
The present findings revealed a significant decrease in 
GSH, SOD and CAT in the rats challenged with 
20mg/kg bw of graded Ciprofloxacin balance with 
concomitant increase in MDA’s lipid peroxidation 
suggestive of decreased oxidative balance. Lipid 
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peroxidation is a significant determinant of the degree of 
free radical generation with MDA being one of the 
products, as well as, an important marker of the process 
of the oxidative stress (Halliwell and Gutterridge, 1994; 
Chaudiere and Ferrari-Iliou, 1999). Fluoroquinolones 
are known to display hepatotoxic effect (Clark et al., 
2001). The studies of (Dhamidharka et al., 1996; 
Pouzauaud et al., 2006) reported that the generation of 
reactive oxygen species by fluoroquinolones resulted in 
cellular damage to liver and kidney. Other researchers 
have reported the induction of reactive oxygen species 
(ROS) by fluoroquinolones, as well as, some other 
antibiotics (Altınordulu and Eraslan, 2009; Páez et al., 
2011). Fluoroquinolones as well as some other 
antibiotics have been demonstrated cause to oxidation of 
macromolecules in some bacteria, resulting in increased 
lipid peroxidation (Páez et al., 2011). 
 
Results from the cardiovascular analysis demonstrated 
Elevated SBP as observed in groups C and D; DBP was 
elevated in all the experimental groups (B, C, D). PP 
reduced in groups B, C and D while MABP increased in 
group B but significantly increased in groups C and D. 
However, HR increased only in group D. Elevated blood 
pressure is critical index of cardiovascular disorder. 
Abnormal changes observed in the cardiovascular 
parameters may be associated with elevated levels of 
triglyceride and low density lipoprotein. Serum 
triglyceride levels have been shown to be an independent 
risk factor for coronary heart disease and are strongly 
determined by low-density lipoprotein (LDL) 
composition, which can be specifically modified by 
dietary lipid source (Jain et al., 2010).  Results from this 
finding agrees with previous investigations by 
Saracoglu, (2009) and Cholongitas et al., (2009) which 
reported that over dose of Ciprofloxacin is associated 
with cardio toxicity. 
 
In conclusion, findings from this study suggests that 
Ciprofloxacin administration at 5mg/kg and 10mg/kg 
had no adverse effect on lipid profile, hepato-reno 
functions and antioxidant status. However, at 20mg/kg, 
Ciprofloxacin resulted to dyslipidaemia, hepato-reno 
dysfunction and increased oxidative radical and 
predisposes to cardiovascular dysfunction. Due to the 
potential adverse effect of Ciprofloxacin and 
greater danger it may portend at 20mg/kg bw, care 
should be taken to avoid possible metabolic and 
cardiovascular disorders   during its therapeutic use.  
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